Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Coya Therapeutics, Inc. - Common Stock (NQ: COYA ) 7.260 +0.520 (+7.72%) Official Closing Price Updated: 4:15 PM EST, Nov 6, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Coya Therapeutics, Inc. - Common Stock < Previous 1 2 3 4 5 Next > Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302 March 21, 2023 By Kenneth Adams, Benzinga Via TheNewswire.com Coya Therapeutics Reveals Proof-of-Concept Data From Small Study With ALS Patients March 21, 2023 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session March 21, 2023 Via Benzinga Reminder: Coya Therapeutics to Host Conference Call Presenting Positive Clinical Data of COYA 302 in Patients with Amyotrophic Lateral Sclerosis (ALS) Today at 8:00am ET March 21, 2023 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics Stock Down 3.79% Since IPO December 30, 2022 Via Benzinga Coya Therapeutics, Inc. Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS) March 21, 2023 From Coya Therapeutics, Inc. Via Business Wire Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy's Laboratories To License And Commercialize COYA 302 March 20, 2023 Coya Therapeutics, Inc. (NASDAQ: COYA) recently announced a worldwide agreement with Dr. Reddy’s Laboratories Limited. Via Benzinga Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy’s Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases March 20, 2023 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics to Host Conference Call Presenting Clinical Data of COYA 302 in Patients with Amyotrophic Lateral Sclerosis (ALS) on March 21, 2023, at 8:00am ET March 09, 2023 From Coya Therapeutics, Inc. Via Business Wire This Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicine’s Next Frontier? March 06, 2023 By David Willey, Benzinga Via TheNewswire.com This Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicine’s Next Frontier? March 06, 2023 This Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicine’s Next Frontier? Via News Direct This Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicine's Next Frontier? March 03, 2023 Texas-based biotech company, Coya Therapeutics (NASDAQ: COYA), is positioning itself as a leader in a promising area of the medical field. Via Benzinga Houston-Based Coya Therapeutics To Present Results From ALS Clinical Study Data For Its Investigational Biologic Combination at the 2023 MDA Clinical & Scientific Conference in Dallas February 28, 2023 Coya Therapeutics, Inc. (NASDAQ: COYA) recently announced the presentation of results from an academic clinical study in patients with Amyotrophic Lateral Sclerosis (ALS) with Coya’s proprietary... Via TheNewswire.com Houston-Based Coya Therapeutics To Present Results From ALS Clinical Study Data For Its Investigational Biologic Combination at the 2023 MDA Clinical & Scientific Conference in Dallas February 28, 2023 Houston-Based Coya Therapeutics To Present Results From ALS Clinical Study Data For Its Investigational Biologic Combination at the 2023 MDA Clinical & Scientific Conference in Dallas Via News Direct Houston-Based Coya Therapeutics To Present Results From ALS Clinical Study Data For Its Investigational Biologic Combination at the 2023 MDA Clinical & Scientific Conference in Dallas February 27, 2023 Coya Therapeutics, Inc. (NASDAQ: COYA) recently announced the presentation of results from an academic clinical study in patients with Amyotrophic Lateral Sclerosis (ALS) with Coya’s proprietary... Via Benzinga Coya Therapeutics to Present ALS Clinical Study Data for its Investigational Biologic Combination at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. February 27, 2023 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics’ Expansion Of Exclusive Worldwide Licensing Agreement With ARscience Biotherapeutics Could Have Outsized Impact On Neurodegenerative And Autoimmune Diseases Treatments February 16, 2023 Coya Therapeutics’ Expansion Of Exclusive Worldwide Licensing Agreement With ARscience Biotherapeutics Could Have Outsized Impact On Neurodegenerative And Autoimmune Diseases Treatments Via News Direct Coya Therapeutics’ Expansion Of Exclusive Worldwide Licensing Agreement With ARscience Biotherapeutics Could Have Outsized Impact On Neurodegenerative And Autoimmune Diseases Treatments February 16, 2023 By Ernest Dela Aglanu, Benzinga Via TheNewswire.com Coya Therapeutics' Expansion Of Exclusive Worldwide Licensing Agreement With ARscience Biotherapeutics Could Have Outsized Impact On Neurodegenerative And Autoimmune Diseases Treatments February 15, 2023 Houston, Texas-based Coya Therapeutics Inc. (NASDAQ: COYA) has just taken a giant leap in making effective proprietary treatments focused on certain neurodegenerative and autoimmune diseases available... Via Benzinga Coya Therapeutics, Inc. Announces Expansion of Exclusive Worldwide Licensing Agreement with ARScience Biotherapeutics, Inc. for Development and Commercialization of COYA 301, Coya’s Low-Dose Interleukin 2 (IL-2) Product Candidate February 15, 2023 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics, Inc. to Present Proof of Concept Clinical Data at Multiple Scientific Conferences Throughout 2023 February 02, 2023 From Coya Therapeutics, Inc. Via Business Wire Stocks That Hit 52-Week Lows On Friday January 27, 2023 During Friday, 24 stocks hit new 52-week lows. Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For January 26, 2023 January 26, 2023 Via Benzinga Coya Therapeutics, Inc. Announces Preclinical Data Supporting the Role of Expanded Regulatory T Cells (Tregs) as Potential Disease-Modifying Treatment in an Animal Model of Alzheimer’s Disease (AD) January 26, 2023 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics, Inc. Announces Closing of $15.25 Million Initial Public Offering January 03, 2023 From Coya Therapeutics, Inc. Via Business Wire Opening Day: Coya Goes Public In Last Week Of Quiet Year December 31, 2022 Coya Therapeutics went public this week, making it the last IPO of the year. Meanwhile, LiveOne announced that Courtside Group filed a registration statement with the SEC for its planned spin-out and... Via Talk Markets < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
